Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight ...

The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

Women in midlife face a difficult trade-off. Many in their 40s to 60s face a high risk of breast cancer, especially during ...

FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...

The FDA has authorized CLAIRITY BREAST, the first AI tool to predict a woman’s 5-year breast cancer risk using routine ...